Randomized Comparison of Coronary Recanalization Versus Placebo for Chronic Occlusion

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  JACC https://doi.org/10.1016/j.jacc.2026.03.027 
Dr. Sarosh Khan  et al.

Points

Researchers conducted the first randomized double-blind trial to determine if percutaneous coronary intervention for chronic total occlusion improves symptoms more effectively than a sham placebo procedure for patients.
The study found that patients receiving the actual intervention experienced thirty-one more angina-free days over a six-month period than those in the control group who received the placebo treatment.
Participants in the angioplasty group were four times more likely to report significant improvements in their chest pain scores and overall quality of life compared to the placebo cohort.
While both groups saw some symptomatic improvement investigators noted that the relief in the intervention group was highly statistically significant and exceeded the expected placebo effects of the procedure.
These results suggest that reopening a totally blocked coronary artery is a safe and effective treatment for stable angina when performed by experienced operators in specialized medical centers.

Summary

The efficacy of percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) in patients with symptomatic stable angina. The ORBITA-CTO trial, a randomized, double-blind, placebo-controlled study, addressed the historical lack of blinded evidence for CTO recanalization. Fifty patients (median age 64 years; 74% male) with single-vessel CTO and a 12-month median history of angina despite optimal medical therapy were randomized to either CTO PCI or a sham placebo procedure. To maintain strict blinding, patients received sedation and auditory isolation during the procedure, while follow-up assessments were conducted by blinded clinical teams.

The findings demonstrated that CTO PCI significantly improves anginal symptoms and quality of life compared to placebo. Over a 168-day follow-up period, the intervention group experienced 31 more angina-free days than the control group. Patients in the PCI cohort were four times as likely to show improvement in their primary angina score, which integrated daily symptomatic episodes and anti-anginal medication requirements. Secondary endpoints, including physician-assessed angina severity and validated quality-of-life questionnaires, similarly favored the intervention group with high statistical significance. Notably, the trial reported zero incidents of death or myocardial infarction, supporting the safety of the procedure in specialized centers.

The data suggest that the physiological benefits of reopening a totally occluded coronary artery extend beyond a mere placebo effect. While the study was limited by its small sample size and the exclusion of highly complex anatomical CTO features, the robust double-blind design provides a definitive benchmark for interventional cardiology. These results indicate that for patients with persistent symptoms, CTO PCI is an effective strategy to reduce the ischemic burden and improve functional status. Future research is warranted to extrapolate these findings to more complex coronary morphologies and to further refine patient selection for this technically demanding procedure.

Link to the article: https://www.jacc.org/doi/10.1016/j.jacc.2026.03.027

References

Khan, S., Sajjad, U., Fawaz, S., Butt, H., Simpson, R., Ibrahim, A., Robertson, C., Kelly, P., Mohdnazri, S. R., Tang, K., Cook, C. M., Demir, O. M., O’Kane, P., Spratt, J. C., Brilakis, E. S., Karamasis, G. V., Shun-Shin, M., Al-Lamee, R., Keeble, T. R., & Davies, J. R. (2026). A randomized, placebo-controlled trial of chronic total occlusion percutaneous coronary intervention in stable angina—Orbita-cto. JACC, S0735109726057451. https://doi.org/10.1016/j.jacc.2026.03.027